Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy
NCT ID: NCT02527902
Last Updated: 2015-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2011-01-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The measure of the activity of the autonomous nervous system, and especially the quantification of its variability, is a means to estimate the cardiovascular risk. The investigators formulate the hypothesis that the variability of the autonomous nervous system is an additional clinical element for the evaluation of the evolutionary risk of renal diseases.
The aim of this study is to compare the variability of the autonomous nervous system during the various evolutionary stages of the renal disease.
The renal disease studied will be IgA nephropathy (IgNA). IgNA is a histologically defined glomerulonephritis (rela biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at list 1+) by immunofluorescence.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quantification of Autonomic Nervous Activity During Hemodialysis
NCT02754986
Analgesia Nociception Index to Explore Autonomic Nervous System in Patients With Continuous Renal Replacement Therapy
NCT06285162
Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.
NCT01579032
Autonomic Nervous System Dysfunction in Patients With End-stage Kidney Disease
NCT05278702
Intravascular Ultrasound Evaluation of Renal Nerves in Different Diseases
NCT02243514
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IgAN with glomerular filtration rate (GFR) >90 ml/min/1.73 m2
Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) \>90 ml/min/1.73 m2
Holter
measure of ANS in IgAN patients
IgAN with GFR 60-89 ml/min/1.73 m2
Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2
Holter
measure of ANS in IgAN patients
IgAN with GFR 30-59 ml/min/1.73 m2
Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2
Holter
measure of ANS in IgAN patients
IgAN with GFR 15-29 ml/min/1.73 m2
Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2
Holter
measure of ANS in IgAN patients
IgAN with GFR < 15ml/min/1.73 m2
Measure of ANS by holter device in IgAN patients with GFR \< 15ml/min/1.73 m2.
Holter
measure of ANS in IgAN patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Holter
measure of ANS in IgAN patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* current kidney transplantation
* Hypertension treated or not,
* Diseases interfering with ANS analysis: cardiac arrhythmia, beta-blocker therapy
* diabetes
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Saint Etienne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Alamartine, PhD
Role: PRINCIPAL_INVESTIGATOR
CHU SAINT-ETIENNE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Saint-Etienne
Saint-Etienne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1008123
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.